You are here

Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183195-01
Agency Tracking Number: R43CA183195
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10225 Barnes Canyon Road suite A104
SAN DIEGO, CA 92121-2734
United States
DUNS: 963248807
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 FABIO TUCCI
 (619) 917-0639
 ftucci@epigenbiosciences.com
Business Contact
 FABIO TUCCI
Phone: (858) 657-0918
Email: ftucci@epigenbiosciences.com
Research Institution
 Stub
Abstract

PROJECT SUMMARY Metastasis is a key factor for poor prognosis in cancer patients. Ovarian cancer is the fifth most common gynecological cancer causing significant mortality among women. Breast cancer is the most common invasive cancer in women and the second-most common cause of death in American women. Triple negative breast cancer tends to be both unresponsive to chemotherapy and more aggressive than other types of breast cancer. New therapies to prevent spread of these cancer types are urgently needed. There is recent scientific evidence that both migration and cytoskeleton rearrangement associated with metastases of these cancer types is controlled by a specific protein kinase. By using a rational design approach that combines structural protein kinase information and optimal ADME properties, we have discovered a novel series of potent kinase inhibitors. The goal of this work is to optimize our newly discovered series of inhibitors as agents to prevent metastasis in triple negative breast cancer and ovar

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government